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€287.96: 55% private expenses and 45% charged to NHS. Hos-
pitalizations created the highest burden (22%, NHS) followed
by home-care and transport (both private). In the last year
26 patients (33%) varied their occupational status due to pain.
Fifty-eight (73%) patients required a caregiver; caregivers were
absent from work in 80% of cases. A strong impairment in
baseline HR-QoL was documented. Patients reported an average
value of 37 in the EQ-VAS (‘pain/discomfort’ and ‘usual activi-
ties’ are the most impaired domains), using the UK conversion
values the mean utility score was 0.07, using the Catalonian it
was 0.10. According to the Oswestry questionnaire, 44% of
patients were considered crippled and 39% severely disabled.
The physical role was the most impaired dimension as measured
with the SF-36. CONCLUSIONS: Our baseline analysis demon-
strates FBSS is a very expensive disease that severely impairs
HR-QoL. Future analyses will evaluate the cost-effectiveness of
SCS and CMM in the treatment of FBSS.
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OBJECTIVES: To evaluate the cost-effectiveness of fentanyl ITS
(iontophoretic transdermal system—IONSYSTM) versus epidural
analgesia (EA) or intravenous patient-controlled analgesia (IV-
PCA) for acute post-operative pain management (POPM) from a
Finnish hospital perspective. METHODS: The cost-effectiveness
of IONSYSTM was assessed using a decision analytic model esti-
mating costs (2008€) and POPM patient outcomes (pain relief,
minor and major POPM-related complications) from surgery
to discharge. Groups receiving 1, 2 or 3 day(s) of IV-PCA or EA
were compared to groups receiving respectively 1, 2 or 3 day(s)
of IONSYSTM. Pain relief data were derived from clinical trials
and published literature. Complication rates were predicted from
a longitudinal hospital database. Resource use included drugs,
consumables, equipment, POPM-related complications and staff
time, the latter derived from expert panels and a literature review.
Costs were based on ofﬁcial tariffs and price lists. RESULTS: The
costs of IONSYSTM for 1, 2 or 3-day groups were €1,825, €2,240
and €2,655. For 1 day of IV-PCA and 1, 2, 3 day(s) of EA
respectively, savings were €70, and €164, €167, €174. For 2 or 3
days of IV-PCA respectively additional costs were €19 and €105.
The percentage of complication-free patients was consistently
higher with IONSYSTM as regards minor and major complica-
tions with increment ranges of [1.44%, 3.95%] and [0.04%,
2.29%], respectively. The percentage of patients reporting no or
mild pain with IONSYSTM was the same as with IV-PCA and
lower than with epidural with respective increments for 1, 2 and
3-day groups of -4.02%, -4.33% and -5.26%. CONCLU-
SIONS: Compared to EA, IONSYSTM offers lower costs and
fewer complications. EA however offers improved pain relief.
Compared to IV-PCA, IONSYSTM dominates the 1-day group
and for the 2 and 3-day groups offers fewer complications at a
higher cost.
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OBJECTIVES: Health Technology Assessment to evaluate the
medical effectiveness and cost-effectiveness of bariatric surgical
procedures in the therapy of morbid obesity in adults compared
to standard interventions. METHODS: Systematic literature
review (published since 2001), targeting adult subjects with
morbid obesity (BMI >= 40 kg/m2 or BMI >= 35 kg/m2 with
severe comorbidities). Relevant publications are identiﬁed by
means of a structured search of 28 databases (e.g. Medline,
Embase, Cochrane Central) on November 12th, 2007. In addition
a manual search of identiﬁed reference lists was conducted. Titles
and abstracts of the identiﬁed publications have been indepen-
dently screened by two experts on evidence based medicine
and health economics. The methodological quality of included
studies have been assessed using the criteria recommended by
the Scottish Intercollegiate Guideline Network (SIGN) Grading
Review Group. Randomised as well as non-randomised studies
are included, case reports and series are not considered. The
methodological quality of the economic publications has been
assesed using checklists of the German Scientiﬁc Working Group
of Technology Assessment for Health Care and the methodologi-
cal guide of the EURONHEED project. RESULTS: Among 5910
retrieved publications, 25 medical articles and seven health eco-
nomic studies met the inclusion criteria. Among the included
medical publications are nine RCTs, 13 papers on non-
randomised clinical trials, and three systematic reviews with
meta-analysis. Within the economic assessment, three CEA and
four systematic reviews have been identiﬁed. Three of the non-
randomised studies assess bariatric vs. conventional procedures.
All other studies compare different surgical procedures among
each other. Follow-up time varies between one and ﬁve years in
the RCT and goes up to eleven years in one clinical trial. Both
medical studies assessing effectiveness of bariatric vs. conven-
tional procedures show a signiﬁcant greater weight loss after
surgery and decline in comorbidities. Diabetes incidence after ten
years is lower in the surgery group, but no signiﬁcant differences
can be seen for hypertension, dislipoproteinemia. Among the
economics publications, three studies evaluated the cost-
effectiveness of certain bariatric surgeries. One study examined
two bariatric operations, adjustable gastric banding and gastric
bypass, for the treatment of obesity in patients with Type 2
diabetes mellitusOne of the studies included deals with a com-
parison of GBP vs. no treatment, whereas the other compares the
two surgical procedures VBG and AGB among each other.
Furthermore, four systematic literature reviews are among the
included economic publications, estimating the cost-effectiveness
of bariatric treatments based on published data. The focus of
the reviews lies both, on the comparison of the cost-effectiveness
among the bariatric procedures, as well as on the comparison to
no treatment at all. CONCLUSIONS: The short and medium
term effectiveness of bariatric procedures on weight loss can be
assumed and is cost-effective. The weight loss is generally accom-
panied by a reduction of comorbidities, in particular diabetes,
and a decreased overall mortality. There is a lack of studies that
focus long term effects and costs. Therefore, based on the avail-
able literature no recommendation can be given with respect to
the choice of a certain bariatric procedure in usual care or to the
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